Photo: DNA
Bharat Biotech's Covaxin Receives GMP Certificate From Hungary
Good Manufacturing Practices (GMP) compliance certificate from Hungary has been granted to Bharat Biotech’s Covid-19 vaccine Covaxin. The company on August 6 took to Twitter saying, “This marks the 1st EUDRAGDMP compliance certificate received by Bharat Biotech from European regulators.” The company stated that it aims to submit its documentation across the globe for emergency use authorization. Besides, it has been registered on the… read-more
Tags: Covaxin, Bharat biotech, Hungary, WHO-GMP
Courtesy: The Hindu
Photo: The Times of India
WHO Commences Review Process Of Covaxin For Emergency Use
Bharat Biotech has submitted all the required documents for Emergency Use Listing (EUL) of "Covaxin" vaccination on July 9th and WHO has began the process for approval, said Minister of State for Health Bharati Pravin Pawar on July 27. Further, she added that the WHO will take a duration of six weeks on the decision. Meanwhile, the Central Government is working relentlessly for the emergency approval of Covaxin.
Tags: WHO, Covaxin, Bharat biotech, Covid-19, Coronavirus Vaccines
Courtesy: News 18
Photo: The Hindu
Brazil Cancels Bharat Biotech's Covaxin Clinical Studies Due To Controversy
Following the controversy related to the deal with the Brazilian government for the supply of 20 million doses of vaccine led to the suspension of clinical studies of 'Bharat Bio-Tech Covaxin.’ It thus terminated Bharat Biotech’s agreement with its partner. The MoU signed with Precisa Medicamentos and Envixia Pharmaceuticals LLC for its Covid-19 vaccine Covaxin for the Brazilian… read-more
Tags: Bharat biotech, Brazil, Covid-19, Covaxin
Courtesy: PTI
Photo: Financial Express
Covaxin's Phase-3 Trial Results Out, Claims To Be 77.8% Effective
Hyderabad-based Bharat Biotech has released the phase-3 clinical trial results of "Covaxin" on July 3, claiming it to be 77.8% successful. Moreover, the company said that it provides 63.6% protection to asymptomatic COVID-19 patients and is 65.2% effective against the SARS-CoV-2 & B.1.617.2 Delta variant. The vaccine is said to be 93.4% effective against severe symptomatic cases. As far as safety is concerned, Covaxin's effects are much… read-more
Tags: Covaxin, clinical trial, Bharat biotech, third phase, Delta Variant
Courtesy: The Siasat Daily
Photo: The Economic Times
Brazil Temporarily Suspends Covaxin's Orders From Bharat Biotech
The Brazilian government temporarily suspended the contract of 20 million Covaxin doses to be supplied by Bharat Biotech on June 30. "As of 29th June 2021, Bharat Biotech has not received any advance payments nor supplied any vaccines to MOH Brazil,” said the company. The contract landed under controversy after the Brazilian Attorney General reportedly initiated a probe into the deal, the suspension is said… read-more
Tags: Covaxin, Brazilian President, Attorney General, Bharat biotech
Courtesy: Deccan Herald
Photo: Reuters
"There Is Nothing Wrong With Covaxin Contract," Says Brazil President
In order to give testimony over the issue of Brazil’s vaccine deal with India’s Bharat Biotech, Luis Miranda, a Brazilian Congressman appears in a bulletproof vest at the Senate Commission on June 25. Opposing the claim President Jair Bolsonaro stated, “There is nothing wrong with the Covaxin contract, there is no overpricing.” However, the death rate due to COVID-19 have jumped to 40% in Africa.
Tags: Covid-19, Covaxin, Bharat biotech, Brazilian President, Jair Bolsonaro
Courtesy: NDTV
Photo: Zee News
Covaxin Failed To Secure Emergency Use Authorisation In US
The emergency use authorisation of Bharat Biotech COVID-19 vaccine 'Covaxin' has been rejected by the US drug regulator. The company will now submit only a biologics license application for 'Covaxin'. Meanwhile, Bharat Biotech has decided to publish its phase-3 clinical trial data in July. Notably, 'Covaxin' has secured an approval in India and is one of those COVID vaccines which are being administered to people.
Tags: Bharat biotech, FDA, United States, Covaxin, Covid-19
Courtesy: Times Now
Photo: Deccan Chronicle
Bharat Biotech To Produce 10 Cr COVID Jabs Per Month By October: Nadda
BJP president JP Nadda on May 30 claimed that Bharat Biotech will produce 10-crore COVID-19 vaccines/month by October. At present, the indigenous vaccine manufacturer is producing 1.3 crore vaccines/month. He also said that now 13 Pharma firms have been permitted to manufacture Covid-19 Vaccines against only two companies. Lashing at the opposition leaders, Nadda said, those who earlier raised doubts over vaccines… read-more
Tags: Covid-19, Coronavirus Vaccines, Bharat biotech, Pharma, JP Nadda
Courtesy: Live Mint
Photo: Business Standard
Bharat Biotech's Covaxin Trials On Kids Likely To Begin In June
Bharat Biotech on May 23 stated it would begin trials of its COVID-19 vaccine Covaxin on children from June. "Kids vaccine trials of Bharat Biotech may get the license in third quarter of this year," stated an official of the company. Besides, the vaccine-maker is also eyeing to increase Covaxin manufacturing capacity to 700Mn doses by 2021 end as "the government placed an advanced purchase order of Rs 1,500 crore".
Tags: Bharat biotech, Covaxin, Covid -19, COVISHIELD
Courtesy: The Times of India
Photo: Business Standard
Adar Poonawalla Sells His Stakes In Panacea Biotech For Rs 118 Cr
Adar Poonawalla on May 17 transferred his entire 5.15% stake in Panacea Biotech to his company Serum Institute of India for Rs 118 crore. In an open market transaction, Poonawalla sold 3.15 million shares of Panacea Biotech at Rs 373.85 each. SII was already holding 4.98% stake in Panacea, hence, this deal stretches the total stake to 10.13%. Panacea has reportedly collaborated with Bharat Biotech for Covaxin production.
Tags: SII, Adar Poonawalla, Panacea Biotech, Covaxin, Bharat biotech
Courtesy: The Economic Times
